Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label single-arm study of macitentan for right ventricular remodeling in symptomatic pulmonary arterial hypertension
MOH_2017-05-22_000449Phase 4Not yet recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Effect of macitentan on right ventricular characteristics and pulmonary hemodynamics. Planned start May 2017; status: not yet recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-05-22_000449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-22_000449.